Authors' results and conclusions: Recently published results from the ENZAMET trial indicate that patients with mHSPC benefit from the addition of enzalutamide to standard first-line treatment in terms of overall survival (OS) and prostate-specific antigen progression-free survival (PSA-PFS). However, the administration of enzalutamide was associated with a higher rate of serious adverse events (AEs) as compared to standard care. Due to the ongoing status of the trial, mature final and long-term data are lacking. However, due to the nature of the open-label study design, a high risk of bias is existent and will remain even with mature data. Since final OS data and health-related quality of life (HRQoL) data are not available yet, the clinical benefit for affected patients cannot be assessed. More mature data, acquired over a longer treatment duration, are required to confirm the present results.

Project Status: Completed

URL for project: https://aihta.at/page/horizon-scanning-in-der-onkologie/en

Year Published: 2019

URL for published report: http://eprints.aihta.at/1216/1/DSD_HSO_Nr.90.pdf

URL for additional information: http://eprints.aihta.at/1216/

English language abstract: An English language summary is available

Publication Type: Full HTA

Country: Austria

Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment

Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99

Contact Name: tarquin.mittermayr@aihta.at

Contact Email: office@aihta.at

Copyright: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)